TrialInternational journal of cancer2022

Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab.

Giulia Martini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.